Abstract
Purpose: This study investigated whether the metabolic avidity of primary tumors and/ or metastatic lymph nodes (LNs) measured by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) was related to survival after surgery in patients with advanced gastric cancer (AGC). Materials and Methods: One hundred sixty-eight patients with AGC who underwent preoperative 18F-FDG PET/CT and curative resection were included. The 18F-FDG avidity of the primary gastric tumor and LNs was determined quantitatively and qualitatively. The diagnostic performance of 18F-FDG PET/CT was calculated, and the prognostic significance of 18F-FDG avidity for recurrence-free survival (RFS) and overall survival (OS) was assessed. Results: In all, 51 (30.4%) patients experienced recurrence, and 32 (19.0%) died during follow-up (median follow-up duration, 35 months; range, 3–81 months); 119 (70.8%) and 33 (19.6%) patients showed 18F-FDG-avid primary tumors and LNs, respectively. 18F-FDG PET/ CT showed high sensitivity (73.8%) for the detection of advanced pathologic T (pT ≥3) stage and high specificity (92.2%) for the detection of advanced pN (≥2) stage. 18F-FDG avidity of LNs was significantly associated with RFS (P=0.012), whereas that of primary tumors did not show significance (P=0.532). Univariate and multivariate analyses revealed that 18F-FDG avidity of LNs was an independent prognostic factor for RFS (hazard ratio=2.068; P=0.029). Conclusions: 18F-FDG avidity of LNs is an independent prognostic factor for predicting RFS. Preoperative 18F-FDG PET/CT can be used to determine the risk and prognosis of patients with AGC after curative resection.
| Original language | English |
|---|---|
| Pages (from-to) | 218-229 |
| Number of pages | 12 |
| Journal | Journal of Gastric Cancer |
| Volume | 18 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2018 Sep 1 |
Fingerprint
Keywords
- F-fluorodeoxyglucose
- Gastric cancer
- Positron emission tomography computed tomography
- Recurrence
ASJC Scopus subject areas
- Oncology
- Gastroenterology
- Cancer Research
Cite this
Preoperative nodal 18F-FDG avidity rather than primary tumor avidity determines the prognosis of patients with advanced gastric cancer. / Kwon, Hyun Woo; An, Liang; Kwon, Hye Ryeong; Park, Sungsoo; Kim, Sungeun.
In: Journal of Gastric Cancer, Vol. 18, No. 3, 01.09.2018, p. 218-229.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Preoperative nodal 18F-FDG avidity rather than primary tumor avidity determines the prognosis of patients with advanced gastric cancer
AU - Kwon, Hyun Woo
AU - An, Liang
AU - Kwon, Hye Ryeong
AU - Park, Sungsoo
AU - Kim, Sungeun
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Purpose: This study investigated whether the metabolic avidity of primary tumors and/ or metastatic lymph nodes (LNs) measured by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) was related to survival after surgery in patients with advanced gastric cancer (AGC). Materials and Methods: One hundred sixty-eight patients with AGC who underwent preoperative 18F-FDG PET/CT and curative resection were included. The 18F-FDG avidity of the primary gastric tumor and LNs was determined quantitatively and qualitatively. The diagnostic performance of 18F-FDG PET/CT was calculated, and the prognostic significance of 18F-FDG avidity for recurrence-free survival (RFS) and overall survival (OS) was assessed. Results: In all, 51 (30.4%) patients experienced recurrence, and 32 (19.0%) died during follow-up (median follow-up duration, 35 months; range, 3–81 months); 119 (70.8%) and 33 (19.6%) patients showed 18F-FDG-avid primary tumors and LNs, respectively. 18F-FDG PET/ CT showed high sensitivity (73.8%) for the detection of advanced pathologic T (pT ≥3) stage and high specificity (92.2%) for the detection of advanced pN (≥2) stage. 18F-FDG avidity of LNs was significantly associated with RFS (P=0.012), whereas that of primary tumors did not show significance (P=0.532). Univariate and multivariate analyses revealed that 18F-FDG avidity of LNs was an independent prognostic factor for RFS (hazard ratio=2.068; P=0.029). Conclusions: 18F-FDG avidity of LNs is an independent prognostic factor for predicting RFS. Preoperative 18F-FDG PET/CT can be used to determine the risk and prognosis of patients with AGC after curative resection.
AB - Purpose: This study investigated whether the metabolic avidity of primary tumors and/ or metastatic lymph nodes (LNs) measured by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) was related to survival after surgery in patients with advanced gastric cancer (AGC). Materials and Methods: One hundred sixty-eight patients with AGC who underwent preoperative 18F-FDG PET/CT and curative resection were included. The 18F-FDG avidity of the primary gastric tumor and LNs was determined quantitatively and qualitatively. The diagnostic performance of 18F-FDG PET/CT was calculated, and the prognostic significance of 18F-FDG avidity for recurrence-free survival (RFS) and overall survival (OS) was assessed. Results: In all, 51 (30.4%) patients experienced recurrence, and 32 (19.0%) died during follow-up (median follow-up duration, 35 months; range, 3–81 months); 119 (70.8%) and 33 (19.6%) patients showed 18F-FDG-avid primary tumors and LNs, respectively. 18F-FDG PET/ CT showed high sensitivity (73.8%) for the detection of advanced pathologic T (pT ≥3) stage and high specificity (92.2%) for the detection of advanced pN (≥2) stage. 18F-FDG avidity of LNs was significantly associated with RFS (P=0.012), whereas that of primary tumors did not show significance (P=0.532). Univariate and multivariate analyses revealed that 18F-FDG avidity of LNs was an independent prognostic factor for RFS (hazard ratio=2.068; P=0.029). Conclusions: 18F-FDG avidity of LNs is an independent prognostic factor for predicting RFS. Preoperative 18F-FDG PET/CT can be used to determine the risk and prognosis of patients with AGC after curative resection.
KW - F-fluorodeoxyglucose
KW - Gastric cancer
KW - Positron emission tomography computed tomography
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=85054526057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054526057&partnerID=8YFLogxK
U2 - 10.5230/jgc.2018.18.e23
DO - 10.5230/jgc.2018.18.e23
M3 - Article
VL - 18
SP - 218
EP - 229
JO - Journal of Gastric Cancer
JF - Journal of Gastric Cancer
SN - 2093-582X
IS - 3
ER -